Prepared by world leaders on this topic, Biomarkers in Cancer Screening and Early Detection offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers, from their discovery and development to their validation, clinical utility, and use in developing personalized cancer treatment.
- Offers a comprehensive, state-of-the-art perspective on the various research and clinical aspects of cancer biomarkers
- Provides immediately actionable information and hopefully also inspiration to move discovery and clinical application forward
- Offers vital knowledge to help develop personalized cancer treatment for individual patients with specific cancers
Sudhir Srivastava, Ph.D., MPH
Senior Scientific Officer, Chief, Cancer Biomarkers Research Group
Division of Cancer Prevention, National Cancer Institute
Bethesda, MD, USA
Dr Srivastava has received many honors and awards and is a member of several scientific committees (AJCC, AACR, All Ireland-NCI Consortium). Dr. Srivastava is a founding member of HUPO (Human Proteome Organisation) and has actively participated in the Plasma Proteome and the Liver Proteome Projects. He is the principal architect of the NCI’s Early Detection Research Network and Alliance of Glycobiologists for the Detection of Cancer and Cancer Risk. He supported the first-ever joint meetings of EDRN-HUPO PPP and Proteomics Jamboree, and recently-held the US-Japan meeting on Glycolic. He has published more than 200 research papers, review articles and commentaries in peer reviewed journals. HJ has edited two other books: Informatics in Proteomics and Nanotechnology for Cancer Detection and Diagnosis (forthcoming). He is also the Editor-in Chief of the journals Disease Markers and Cancer Biomarkers.